Fig. 1
Characterization of EO771/NY-BY-1 transfectant clones. EO771/NY-BR-1 transfectant clones generated by transfection of EO771 cells with a linearized plasmid pcDNA3.1-NY-BR-1 followed by limiting dilution were characterized for NY-BR-1 expression in vitro and the ability to form tumors in vivo. a NY-BR-1 protein expression (159 kDa) in the selected clones was analyzed by Western blot. β-actin (42 kDa) was used as a loading control. b HLA-DRB1*0401tg mice were injected s.c. on the right flank with 2 × 105 EO771, EONY #9 or EONY #17 cells and tumor growth was monitored for 18 days post cell injection. Error bars represent SEM (n = 10). Tumor area was measured and statistical analysis was performed using a mixed linear model with random intercept for animal. Difference between cell lines was highly significant (p < 0.0001); pairwise comparisons: *** p < 0.0001; * p = 0.0157